Elephas Biosciences
1 known investors
Elephas develops elive, a live-tissue platform technology that predicts immunotherapy response in cancer patients by measuring real-time immune activity in intact tumor tissue. The company serves oncologists and patients to enable personalized cancer treatment selection.
BiotechDigital HealthHealthtechMedical Devices
Investors · 1
In the news
- Biomarker Testing Startup Funding (2026) – New Market Pitchnewmarketpitch.com · 2026
- Elephas Biosciences Raises $40M in Series B-2 Fundingfinsmes.com · 2025
- Elephas Biosciences raises $40 million to launch predictive immunotherapy platformbiztimes.com · 2025
- ELEPHAS BIOSCIENCES RAISES $40M TO ACCELERATE COMMERCIALIZATION OF ITS LIVE TUMOR PROFILING PLATFORMprnewswire.com · 2025
- Elephas Biosciences: Oncology Imaging Diagnostics Platform Company Raises $55 Millionpulse2.com · 2024
- Elephas Biosciences raises $55 million led by Madison-based investors - Milwaukee Business Journalbizjournals.com · 2024